IL-15 inhibitor BNZ-1 is safe and effective in T-cell LGLL, gene therapy trial for Wiskott-Aldrich syndrome, and ethical framework to select patients for CAR T-cell therapy

Germline predisposition variants occur in all age groups in MDS, αβ-haplo-HCT excels in children with acute leukemias/MDS, and poor outcomes after CAR T cell failure in B-cell lymphomas: In this week’s episode, research shows that in patients with myelodysplastic syndromes, or MDS, the frequency of pathogenic or likely pathogenic germline variants is relatively high across all age groups, not just younger patients. Based on these results, by Blood Podcast

20 min listen

Season 1, Episode 7: This week’s episode will review treatment for secondary prevention of venous thromboembolism in children, a therapeutic strategy for relapsed or refractory B-cell acute lymphoblastic leukemia, Ivosidenib monotherapy in patients with newly diagnosed AML wi by Blood Podcast

19 min listen

$Season 1, Episode 7: This week’s episode will review treatment for secondary prevention of venous thromboembolism in children, a therapeutic strategy for relapsed or refractory B-cell acute lymphoblastic leukemia, Ivosidenib monotherapy in patients with newly diagnosed AML wi$

Season 2, Episode 9: In this week’s episode, we will review a study that provides further evidence of poor prognosis in patients with multiple myeloma who have “double hit” mutations targeting TP53, examine the early use of BCR-ABL1 kinetics to predict the likelihood of treat by Blood Podcast

16 min listen

MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for ALL, and BAX variants and resistance to BH3-mimetics in AML by Blood Podcast

19 min listen

Season 1, Episode 51: In this week’s episode, we will learn more about T-cells from SARS-CoV-2-infected individuals, review a study that describes the rapid clinical and histologic response to anti-PD1 first-line therapy in early-stage, unfavorable Hodgkin lymphoma, and discus by Blood Podcast

17 min listen

Cell therapy options for chemo-sensitive DLBCL, PIGA mutations in a novel subtype of hemochromatosis, and triplet combination therapy in high-risk CLL: In this week's podcast, we’ll compare the efficacy of autologous stem cell transplant to CAR T-cell therapy for relapsed diffuse large B-cell lymphoma, learn more about a novel subtype of hemochromatosis caused by constitutional PIGA mutations, and discus by Blood Podcast

21 min listen

Cancer Topics - My Approach to Refractory Diffuse Large B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma or DLBCL is the most common type of lymphoma. Much progress has been made in treatment of the disease lately, particularly with emergence of CAR T-cell therapy, but not all patients are benefiting from it. This episode of... by ASCO Education

27 min listen

$Cancer Topics - My Approach to Refractory Diffuse Large B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma or DLBCL is the most common type of lymphoma. Much progress has been made in treatment of the disease lately, particularly with emergence of CAR T-cell therapy, but not all patients are benefiting from it. This episode of...$

Nicole Lamanna, MD - Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management: Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

53 min listen

Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss by Blood Podcast

23 min listen

ASH19 special report: Blood & Cancer takes you behind the podium at the American Society of Hematology annual meeting for an in-depth look at the latest developments in anemia and myelodysplastic syndrome, chimeric antigen receptor (CAR) T-cell therapy for mantle cell... by Blood & Cancer

31 min listen

Spotlight on Immunotherapy at ASCO22: Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh’s Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities,... by ASCO Daily News

27 min listen

Season 1, Episode 40: In this week’s episode, we will learn more about the pre-clinical and clinical development of optimized, bivalent, tandem CD20 and CD19 chimeric antigen receptor T cells for treatment of relapsed/refractory non-Hodgkin lymphoma, examine a study that revea by Blood Podcast

16 min listen

$Season 1, Episode 40: In this week’s episode, we will learn more about the pre-clinical and clinical development of optimized, bivalent, tandem CD20 and CD19 chimeric antigen receptor T cells for treatment of relapsed/refractory non-Hodgkin lymphoma, examine a study that revea$

Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD by Blood Podcast

22 min listen

Novel high-risk subtypes in adult B-ALL, Liso-cel CAR-T therapy in CLL, and liquid biopsies in large B-cell lymphomas: In this week's podcast, we’ll cover a research article that describes two novel subgroups of adult B-cell ALL with high expression of CDX2 and IDH mutations that are linked to poor prognosis. Next, we'll cover results from TRANSCEND CLL 004, a phase 1 stu by Blood Podcast

18 min listen

33. B-Cell Depleting Therapies and COVID-19: This week we welcome Dr. Alfred Kim to our show as we discuss B-Cell depleting therapies and how patients on these drugs may be more susceptible to COVID-19. During which, Dr. Kim takes us back to the beginning of the pandemic and how he and his... by ACR on Air

46 min listen

Season 2, Episode 13: In this week’s episode, we will learn more about the feasibility of combining IDH inhibitors with intensive chemotherapy in patients with newly diagnosed IDH-mutant AML, review a phenotypic and functional analysis of the inflammatory infiltrate in the Lan by Blood Podcast

18 min listen

Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human beta cells against proinflammatory insults by PaperPlayer biorxiv cell biology

20 min listen

2022 Episode 6 – Three Basic Targets: Diabetes is more than a blood sugar problem by Know Diabetes by Heart™ Professional Education Podcast Series

40 min listen